GSK PLC closed 25.31% below its 52-week high of £18.24, which the company reached on May 16th.

Rating upgraded from 66 to 73 Tuesday — a welcome improvement, but still shy of the 80 or better score you prefer to see.

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...

China’s response to new United States (U.S.) tariffs could complicate the supply of important medicines, an analysis of data ...

At its first meeting under the new administration, the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted on recommendations for several ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

ShareIt does not take rocket science to understand the importance and imperative of the factors and features that act as catalysts to increased economic productivity. Chief amongst these are solid ...

Abu Dhabi, brings together key partners including PureHealth’s Rafed, AD Ports Group’s Khalifa Economic Zones Abu Dhabi (KEZAD), Abu ...

CDC panel expands Pfizer and GSK RSV vaccine use to high-risk adults 50–59, building on earlier recommendations for older ...

GSK has secured the first regulatory approval for Blenrep since the antibody-drug conjugate’s global market withdrawal in 2022. | GSK has secured the first regulatory approval for Blenrep since the ...

The UK on Thursday authorized GSK’s Blenrep to treat certain multiple myeloma patients in two different regimens, marking the drug’s first approval worldwide since it was pulled from the US and other ...